Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice
Biomedicine & Pharmacotherapy 109:167-173, 2019
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice
Physiology and Behavior 192:72-81, 2018
Chemical Strategies for Half-life Extension of Biopharmaceuticals: Lipidation and its Alternatives
ACS Medicinal Chemistry Letters 9(7):577-580, 2018
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Journal of Peptide Science 23(12):845–854, 2017
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes
European Journal of Pharmacology 815:181–189, 2017
Enteroendocrine K and L cells in healthy and type 2 diabetic individuals
Diabetologia 61(2):284–294, 2017
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues
Journal of Medicinal Chemistry 60(17):7434–7446, 2017
A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
ACS Chemical Biology 12(8):2107–2116, 2017